201 related articles for article (PubMed ID: 30244101)
21. Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Lin CM; Chang LC; Shau WY; Chen CL; Yao CY; Tien FM
BMC Cancer; 2023 May; 23(1):446. PubMed ID: 37193978
[TBL] [Abstract][Full Text] [Related]
22. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
24. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.
Kumar SK; Lacy MQ; Dispenzieri A; Buadi FK; Hayman SR; Dingli D; Gay F; Sinha S; Leung N; Hogan W; Rajkumar SV; Gertz MA
Cancer; 2012 Mar; 118(6):1585-92. PubMed ID: 22009602
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
[TBL] [Abstract][Full Text] [Related]
26. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
27. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
28. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment.
Armeson KE; Hill EG; Costa LJ
Bone Marrow Transplant; 2013 Apr; 48(4):562-7. PubMed ID: 22964593
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Doo NW; Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Joyce T; Harrison SJ
Leuk Lymphoma; 2013 Jul; 54(7):1465-72. PubMed ID: 23121086
[TBL] [Abstract][Full Text] [Related]
31. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
[TBL] [Abstract][Full Text] [Related]
32. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
van de Velde H; Londhe A; Ataman O; Johns HL; Hill S; Landers E; Berlin JA
Eur J Haematol; 2017 Mar; 98(3):269-279. PubMed ID: 27859769
[TBL] [Abstract][Full Text] [Related]
33. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Biran N; Jacobus S; Vesole DH; Callander NS; Fonseca R; Williams ME; Abonour R; Katz MS; Rajkumar SV; Greipp PR; Siegel DS
Blood Cancer J; 2016 Sep; 6(9):e466. PubMed ID: 27588519
[TBL] [Abstract][Full Text] [Related]
34. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
Hahn T; Wingard JR; Anderson KC; Bensinger WI; Berenson JR; Brozeit G; Carver JR; Kyle RA; McCarthy PL
Biol Blood Marrow Transplant; 2003 Jan; 9(1):4-37. PubMed ID: 12533739
[TBL] [Abstract][Full Text] [Related]
35. Is there still a role for stem cell transplantation in multiple myeloma?
Mina R; Lonial S
Cancer; 2019 Aug; 125(15):2534-2543. PubMed ID: 30985927
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
37. Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.
Mainou M; Madenidou AV; Liakos A; Paschos P; Karagiannis T; Bekiari E; Vlachaki E; Wang Z; Murad MH; Kumar S; Tsapas A
Eur J Haematol; 2017 Jun; 98(6):563-568. PubMed ID: 28178364
[TBL] [Abstract][Full Text] [Related]
38. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
39. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
40. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]